| Name | Title | Contact Details |
|---|
Northwest Florida Blood Ctr is a Pensacola, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Lebanon Nursing and Rehab is a Lebanon, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Medical Billing Management Inc is a Los Angeles, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Founded in 1908, Hu-Friedy has since become a world leader in dental instrument manufacturing. Today, we take a broader view of the value we offer our customers. We are focused on delivering the highest quality product, service, and community experience in the dental industry in order to help dental professionals perform at their best. Our 10,000 dental instruments and product solutions are sold in over 100 countries, and we have more than 600 employees representing and growing our brand around the world. Headquartered in Chicago, we have offices and distribution centers in the Netherlands, Italy, Germany, China, and Japan, and a sales force spread over 30 different countries.
Kymera is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. Kymera’s proprietary targeted protein degradation platform, called Pegasus, enables us to discover highly selective small molecule protein degraders with activity against disease-causing proteins throughout the body. We believe that our small molecule protein degraders have significant advantages over existing therapies and allow us to address a large portion of the human genome that was previously intractable with traditional modalities. Kymera focuses on biological pathways that have been clinically validated but where key biological nodes/proteins have not been drugged or have been inadequately drugged. To date, we have utilized our Pegasus platform to design novel protein degraders focused in the areas of immunology-inflammation and oncology, and continue to apply our platform’s capabilities to additional therapeutic areas.